Tomohiro Yamauchi
Head of Global Scouting & Transaction Astellas Pharma
Tomohiro Yamauchi, Ph.D. Executive Director, Global Head of Scouting & Transaction Oncology, Business Development, Astellas Pharma Dr. Yamauchi has worked at Astellas for 16+ years in various roles with increasing responsibility in Business Development, R&D, Corporate and Portfolio Strategy to lead multiple business transactions (including M&A, in-/out-licensing, new company creation, asset sale, clinical combo trial collaboration and CDx collaboration), pipeline prioritization and portfolio management. He has more than 10 years’ experience of research in oncology and published several scientific papers in well-recognized journals, including EMBO J. and Clinical Cancer Res. Prior to joining Astellas, he served as a research associate in RIKEN, Japan, and obtained a Ph.D. in Medicine from Tsukuba University and also had the clinical pharmacist license in Japan.
Seminars
What is this session?
- With a high concentration of relevant companies in one place, the pharma icebreaker tables offer a guaranteed opportunity for face-to-face interactions. Whether you’re connected on the One-on-One Partnering™ portal or not, this is a formal opportunity to introduce yourself and your organization
How is this organized?
- Two weeks out from the conference, pharma will review attending biotech and biotech will review attending pharma, with both making selections to meet with companies they haven’t scheduled meetings with yet
- With these selections, we will build a schedule of company rotations through each pharma’s table, across 90 minutes
- This ensures you meet face-to-face with priority companies and can introduce yourself to new pharma contacts early in the event. Don’t miss out on this unique chance to expand your network and forge valuable connections!
- Understanding why pharma would invest. What gap are the innovative technologies filling and what is the sentiment for dealmaking right now?
- What do pharma need to see? Sharing direction into what is expected when approaching pharma as a partner
- Insights into how biotech can differentiate in crowded markets
